Latest revenue
$20.7M
as of 2026-03-31
Latest net income
$-99.1M
as of 2026-03-31
Net margin
-477.7%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AGIO is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.70B
- Enterprise value
- $1.58B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.53×
- Dividend yield
- 0.0%
- 52-wk high
- $45.99
- 52-wk low
- $22.24
- Beta
- —
- Shares out
- 59.9M
5-year trend
What this company does
Item 1. Business General We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Business Overview Rare diseases The lead product candidate in our portfolio, mitapivat, is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment…
AI summary unavailable — showing raw filing excerpt
Generated from AGIO's filing dated 2026-02-12
Key risks
Table of Contents Item 1A. Risk Factors The following risk factors and other information included in this Annual Report on Form 10-K should be carefully considered. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Please see page 1 of this Annual Report on Form 10-K for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially…
AI summary unavailable — showing raw filing excerpt
Generated from AGIO's filing dated 2026-02-12
Profitability
Operating margin
-873.9%
25.1%Net margin
-764.0%
141.4%Return on equity
-34.6%
179.1%Return on assets
-31.8%
178.6%Leverage
Debt / equity
0.09×
10.0%Long-term debt / equity
0.00×
100.0%Debt / assets
8.0%
9.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $20.7M | +137.7% | $-99.1M | -11.0% | -477.7% |
Q4 2025 2025-12-31 | $20.0M | +86.1% | $-108.0M | -233.1% | -541.1% |
Q3 2025 2025-09-30 | $12.9M | +43.7% | $-103.4M | -113.4% | -803.1% |
Q2 2025 2025-06-30 | $12.5M | +44.6% | $-112.0M | -16.5% | -899.4% |
Q1 2025 2025-03-31 | $8.7M | +6.6% | $-89.3M | -9.5% | -1023.3% |
Q4 2024 2024-12-31 | $10.7M | — | $81.1M | — | 756.2% |
Q3 2024 2024-09-30 | $9.0M | +21.2% | $770.2M | +943.4% | 8592.7% |
Q2 2024 2024-06-30 | $8.6M | +28.4% | $-96.1M | -14.7% | -1115.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AGIO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$6.1M
Net activity
−$6.1M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AGIO
Institutional value
$810.8M
Total shares held
25.7M
Distinct holders
126
-109 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.8M | $194.7M | +519.5K (+9.9%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.6M | $89.1M | — | New |
| 3 | Lynx1 Capital Management LP | 2.6M | $88.3M | +2.5M (+3179.9%) | Added |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.6M | $88.3M | — | New |
| 5 | Erste Asset Management GmbH | 2.7M | $80.1M | -100.0K (-3.6%) | Trimmed |
| 6 | DIMENSIONAL FUND ADVISORS LP | 1.2M | $38.9M | +147.3K (+14.7%) | Added |
| 7 | Nuveen, LLC | 722.3K | $24.4M | +424.4K (+142.5%) | Added |
| 8 | JANE STREET GROUP, LLC | 685.2K | $23.2M | -435.8K (-38.9%) | Trimmed |
| 9 | SCS Capital Management LLC | 612.9K | $20.7M | +14.1K (+2.4%) | Added |
| 10 | Artisan Partners Limited Partnership | 481.5K | $16.3M | -23.0K (-4.6%) | Trimmed |
| 11 | Connor, Clark & Lunn Investment Management Ltd. | 450.1K | $15.2M | -112.5K (-20.0%) | Trimmed |
| 12 | Legal & General Group Plc | 423.9K | $14.3M | +95.7K (+29.2%) | Added |
| 13 | VANGUARD FIDUCIARY TRUST CO | 382.0K | $12.9M | — | New |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 327.5K | $11.1M | +84.8K (+34.9%) | Added |
| 15 | KENNEDY CAPITAL MANAGEMENT LLC | 275.5K | $9.3M | +209.8K (+319.6%) | Added |
| 16 | Bank of New York Mellon Corp | 186.8K | $6.3M | -10.1K (-5.1%) | Trimmed |
| 17 | GROUP ONE TRADING LLC | 173.3K | $5.9M | +6.7K (+4.0%) | Added |
| 18 | Invesco Ltd. | 151.4K | $5.1M | +8.8K (+6.2%) | Added |
| 19 | JPMORGAN CHASE & CO | 151.6K | $4.5M | -100.2K (-39.8%) | Trimmed |
| 20 | UBS Group AG | 132.5K | $4.5M | +5.9K (+4.6%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AGIO's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.